WallStSmart

Honeywell International Inc (HON)vsResMed Inc (RMD)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Honeywell International Inc generates 594% more annual revenue ($37.44B vs $5.40B). RMD leads profitability with a 27.5% profit margin vs 12.6%. RMD appears more attractively valued with a PEG of 1.39. RMD earns a higher WallStSmart Score of 70/100 (B).

HON

Buy

50

out of 100

Grade: C-

Growth: 2.7Profit: 7.5Value: 7.3Quality: 5.0

RMD

Strong Buy

70

out of 100

Grade: B

Growth: 6.7Profit: 9.5Value: 8.7Quality: 8.3
Piotroski: 6/9Altman Z: 4.34
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

HONSignificantly Overvalued (-416.2%)

Margin of Safety

-416.2%

Fair Value

$47.19

Current Price

$225.79

$178.60 premium

UndervaluedFair: $47.19Overvalued
RMDUndervalued (+14.4%)

Margin of Safety

+14.4%

Fair Value

$303.30

Current Price

$226.31

$76.99 discount

UndervaluedFair: $303.30Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

HON3 strengths · Avg: 8.7/10
Market CapQuality
$143.53B9/10

Large-cap with strong market position

Return on EquityProfitability
26.1%9/10

Every $100 of equity generates 26 in profit

Free Cash FlowQuality
$1.12B8/10

Generating 1.1B in free cash flow

RMD4 strengths · Avg: 9.5/10
Operating MarginProfitability
35.2%10/10

Strong operational efficiency at 35.2%

Altman Z-ScoreHealth
4.3410/10

Safe zone — low bankruptcy risk

Return on EquityProfitability
25.7%9/10

Every $100 of equity generates 26 in profit

Profit MarginProfitability
27.5%9/10

Keeps 28 of every $100 in revenue as profit

Areas to Watch

HON4 concerns · Avg: 3.5/10
PEG RatioValuation
2.014/10

Expensive relative to growth rate

P/E RatioValuation
32.5x4/10

Premium valuation, high expectations priced in

Price/BookValuation
10.3x4/10

Trading at 10.3x book value

Revenue GrowthGrowth
-3.3%2/10

Revenue declined 3.3%

RMD0 concerns · Avg: 0/10

No major concerns identified

Comparative Analysis Report

WallStSmart Research

Bull Case : HON

The strongest argument for HON centers on Market Cap, Return on Equity, Free Cash Flow.

Bull Case : RMD

The strongest argument for RMD centers on Operating Margin, Altman Z-Score, Return on Equity. Profitability is solid with margins at 27.5% and operating margin at 35.2%. Revenue growth of 11.0% demonstrates continued momentum.

Bear Case : HON

The primary concerns for HON are PEG Ratio, P/E Ratio, Price/Book.

Bear Case : RMD

No major red flags identified for RMD, but monitor valuation.

Key Dynamics to Monitor

HON profiles as a declining stock while RMD is a mature play — different risk/reward profiles.

HON carries more volatility with a beta of 0.90 — expect wider price swings.

RMD is growing revenue faster at 11.0% — sustainability is the question.

HON generates stronger free cash flow (1.1B), providing more financial flexibility.

Bottom Line

RMD scores higher overall (70/100 vs 50/100), backed by strong 27.5% margins and 11.0% revenue growth. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Honeywell International Inc

INDUSTRIALS · CONGLOMERATES · USA

Honeywell International Inc. is an American publicly traded, multinational conglomerate headquartered in Charlotte, North Carolina. It primarily operates in four areas of business: aerospace, building technologies, performance materials and technologies (PMT), and safety and productivity solutions (SPS).

ResMed Inc

HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA

ResMed is a San Diego, California-based medical equipment company. It primarily provides cloud-connectable medical devices for the treatment of sleep apnea (such as CPAP devices and masks), chronic obstructive pulmonary disease (COPD), and other respiratory conditions.

Visit Website →

Want to dig deeper into these stocks?